Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Terpos

Showing results (41-50 of 101) with videos related to

Pageof 11
Sort By:
Acta Haematologica|October 2, 2008
Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C in patients with congenital coagulation disordersO Katsarou, G Theodosiades, P Ioannidou, et al.
Haematologia|September 5, 1998
Systemic lupus erythematosus presenting as myelofibrosisK Konstantopoulos, E Terpos, H Prinolakis, et al.
Leukemia|August 5, 2005
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratioE Terpos, D Mihou, R Szydlo, et al.
Blood Cancer Journal|June 6, 2015
Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo stagingE Kastritis, M Gavriatopoulou, M A Dimopoulos, et al.
British Journal of Haematology|February 13, 2001
Bone resorption is increased in young adults with thalassaemia majorE Voskaridou, M C Kyrtsonis, E Terpos, et al.
Leukemia|August 23, 2001
Prognostic evaluation of the microvascular network in myelodysplastic syndromesP Korkolopoulou, E Apostolidou, P M Pavlopoulos, et al.
Leukemia|September 5, 2008
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesisE Terpos, E Kastritis, M Roussou, et al.
Leukemia|June 25, 2004
Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myelomaE Terpos, M Politou, R Szydlo, et al.
Leukemia|July 6, 2012
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myelomaM A Dimopoulos, M Roussou, M Gkotzamanidou, et al.
Leukemia|July 10, 2009
Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myelomaM Roussou, A Tasidou, M A Dimopoulos, et al.
Pageof 11

Showing results (41-50 of 101) with videos related to

Sort By:
Pageof 11
Acta Haematologica|October 2, 2008
Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C in patients with congenital coagulation disordersO Katsarou, G Theodosiades, P Ioannidou, et al.
Haematologia|September 5, 1998
Systemic lupus erythematosus presenting as myelofibrosisK Konstantopoulos, E Terpos, H Prinolakis, et al.
Leukemia|August 5, 2005
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratioE Terpos, D Mihou, R Szydlo, et al.
Blood Cancer Journal|June 6, 2015
Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo stagingE Kastritis, M Gavriatopoulou, M A Dimopoulos, et al.
British Journal of Haematology|February 13, 2001
Bone resorption is increased in young adults with thalassaemia majorE Voskaridou, M C Kyrtsonis, E Terpos, et al.
Leukemia|August 23, 2001
Prognostic evaluation of the microvascular network in myelodysplastic syndromesP Korkolopoulou, E Apostolidou, P M Pavlopoulos, et al.
Leukemia|September 5, 2008
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesisE Terpos, E Kastritis, M Roussou, et al.
Leukemia|June 25, 2004
Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myelomaE Terpos, M Politou, R Szydlo, et al.
Leukemia|July 6, 2012
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myelomaM A Dimopoulos, M Roussou, M Gkotzamanidou, et al.
Leukemia|July 10, 2009
Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myelomaM Roussou, A Tasidou, M A Dimopoulos, et al.
Pageof 11